BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubrutinib in Patients with Mantle Cell Lymphoma in Presentations at the 15th International Conference on Malignant Lymphoma (ICML)
read more...
Jun 18, 2019
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
read more...
Jun 17, 2019
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
read more...
Jun 14, 2019
BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)
read more...
Jun 14, 2019
BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)
read more...
Jun 12, 2019
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
read more...
Jun 05, 2019
BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
read more...
Jun 04, 2019
BeiGene Chief Executive Officer John V. Oyler Elected to BIO Board of Directors
read more...
Jun 01, 2019
BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting
read more...
May 30, 2019
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
read more...
May 30, 2019
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
read more...
May 16, 2019
BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
read more...
May 09, 2019
BeiGene Reports First Quarter 2019 Financial Results
read more...
Apr 09, 2019
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
read more...
Apr 01, 2019
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
read more...
Mar 06, 2019
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
read more...
Mar 04, 2019
BeiGene to Present at Upcoming Investor Conferences
read more...
Feb 27, 2019
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
read more...
Feb 22, 2019
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
read more...
Feb 19, 2019
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
read more...
